



BC Centre for Disease Control
Provincial Health Services Authority

Immunization Programs and Vaccine Preventable Diseases Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: December 19, 2022

Administrative Circular: 2022:53

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products**

Upon direction of Dr. Bonnie Henry, Provincial Health Officer, and Dr. Penny Ballem, Operations Lead for the Influenza Program, BCCDC is expanding the indication for administration of FLUAD®, adjuvanted trivalent influenza vaccine. This will allow for use of up to 100,000 doses of FLUAD® remaining in BC, with the majority in pharmacies. The alternative of purchasing additional supplies of age-appropriate vaccine would result in several days delay.

Part 4 – Biological Products

Influenza Vaccines

Intended Use of Influenza Vaccines

The table has been updated to indicate that FLUAD® may be offered to those 50-64 years of age if an age appropriate vaccine is not available. Additional informed consent should include information that this product has not been authorized by Health Canada for use in this age group, and recipients may experience a higher rate of side effects, especially pain at the injection site, than with standard formulation influenza vaccine.

Please remove page number: 1 dated November 25, 2022

Please add new page number: 1 dated December 2022

Trivalent Inactivated Influenza Vaccine (Inactivated Subunit, Adjuvanted) (TIIV) Fluad®

A footnote has been added to the INDICATIONS section to indicate that FLUAD® may be offered to those 50-64 years of age if an age appropriate vaccine is not available. Additional informed consent should include information that this product has not been authorized by Health Canada for use in this age group, and recipients may experience a higher rate of side effects, especially pain at the injection site, than with standard formulation influenza vaccine.

Please remove page numbers: 1 & 2 dated November 2022

Please add new page numbers: 1 & 2 dated December 2022

Page 1 of 2

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHS Sc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health,
Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease,
Population and Public Health Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division